5 articles
Demis Hassabis confirmed that Isomorphic Labs' first AI-designed cancer drug will enter Phase 1 clinical trials in 2026, built on the AlphaFold-derived IsoDDE platform and backed by $3 billion in Lilly and Novartis partnerships.
Google DeepMind open-sourced AlphaGenome, an AI model published in Nature that predicts DNA function across 1 million base pairs, already used by nearly 3,000 scientists worldwide for cancer and disease research.
The LIGAND-AI consortium launched with over 60 million euros in EU funding, bringing 18 partners led by Pfizer and the SGC together to generate open datasets of protein-ligand interactions for training AI drug discovery models.
Insilico Medicine announced an $888M oncology partnership with Servier days after raising $292M in the largest Hong Kong biotech IPO of 2025, with shares surging 45% on debut.
Insilico Medicine and Hisun Pharma nominated a preclinical candidate in just 8 months using the Pharma.AI platform, dramatically compressing a process that typically takes 2.5 to 4 years in traditional drug discovery.